ES2548884T3 - Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes - Google Patents

Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes Download PDF

Info

Publication number
ES2548884T3
ES2548884T3 ES10179073.1T ES10179073T ES2548884T3 ES 2548884 T3 ES2548884 T3 ES 2548884T3 ES 10179073 T ES10179073 T ES 10179073T ES 2548884 T3 ES2548884 T3 ES 2548884T3
Authority
ES
Spain
Prior art keywords
particles
magnesium stearate
lactose
powder
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10179073.1T
Other languages
English (en)
Spanish (es)
Inventor
David Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33548732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548884(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Application granted granted Critical
Publication of ES2548884T3 publication Critical patent/ES2548884T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Steroid Compounds (AREA)
ES10179073.1T 2004-11-23 2005-11-23 Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes Active ES2548884T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0425758.0A GB0425758D0 (en) 2004-11-23 2004-11-23 Preparation of pharmaceutical compositions
GB0425758 2004-11-23

Publications (1)

Publication Number Publication Date
ES2548884T3 true ES2548884T3 (es) 2015-10-21

Family

ID=33548732

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10179073.1T Active ES2548884T3 (es) 2004-11-23 2005-11-23 Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes
ES10151576.5T Active ES2490240T3 (es) 2004-11-23 2005-11-23 Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes
ES05808842T Active ES2340599T3 (es) 2004-11-23 2005-11-23 Formulaciones de polvo seco para inhalador que comprenden particulas modificadas en la superficie con aditivos antiadherentes.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10151576.5T Active ES2490240T3 (es) 2004-11-23 2005-11-23 Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes
ES05808842T Active ES2340599T3 (es) 2004-11-23 2005-11-23 Formulaciones de polvo seco para inhalador que comprenden particulas modificadas en la superficie con aditivos antiadherentes.

Country Status (16)

Country Link
US (4) US20080127972A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP2311434B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5339401B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN101106975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE456363T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2589514C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602005019192D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK2311434T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2548884T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB0425758D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE027465T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CN04336A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL1814521T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT2311434E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2174653T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006056812A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024009079A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
WO2008078730A1 (ja) 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
EP2141989B1 (en) * 2007-04-11 2013-09-11 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
DK2230934T3 (da) 2007-12-14 2012-11-26 Aerodesigns Inc Afgivelse af aerosoliserbare næringsmiddelprodukter
WO2010007446A1 (en) 2008-07-18 2010-01-21 Prosonix Limited Process for improving crystallinity of fluticasone particles
CN108434126B (zh) 2009-03-26 2021-11-19 普马特里克斯营业公司 治疗肺病的干粉配方与方法
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
EP2421514A2 (en) * 2009-04-24 2012-02-29 Schering Corporation Agglomerate formulations useful in dry powder inhalers
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
TR201811349T4 (tr) * 2010-04-01 2018-09-21 Chiesi Farm Spa İnhalasyon i̇çi̇n kuru toz taşiyici parti̇külleri̇n hazirlanmasi i̇çi̇n proses.
MX2012012045A (es) * 2010-04-21 2012-12-17 Chiesi Farma Spa Proceso para proporcionar particulas con cargas electrostaticas reducidas.
CN102309456B (zh) * 2010-07-02 2013-05-01 北京化工大学 一种厄贝沙坦纳微复合粉体与片剂及其制备方法
CN103200938B (zh) * 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
ES2899621T3 (es) * 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
AU2013225982B2 (en) 2012-02-29 2017-11-30 Pulmatrix, Inc. Inhalable dry powders
AU2013234081B2 (en) 2012-03-13 2017-02-02 Respivert Limited Crystalline PI3 kinase inhibitors
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN103588846B (zh) * 2012-08-15 2016-08-03 重庆华邦制药有限公司 一种丙酸氟替卡松微粒的制备方法及其用途
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
HK1218855A1 (zh) * 2013-04-30 2017-03-17 Otitopic Inc. 干粉製劑及使用方法
SI3409270T1 (sl) 2013-07-11 2021-07-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
WO2015054280A1 (en) 2013-10-08 2015-04-16 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
PL3107548T3 (pl) 2014-02-20 2022-10-31 Otitopic Inc. Suche formulacje w proszku do inhalacji
CN106659686A (zh) 2014-04-04 2017-05-10 拉姆医疗公司 用于治疗年龄相关病况的可吸入雷帕霉素制剂
EA201692456A1 (ru) 2014-07-09 2017-08-31 Арвен Иладж Санайи Ве Тиджарет А.Ш. Способ получения составов для ингаляции
ES2942297T3 (es) * 2014-07-31 2023-05-31 Vectura Inc Formulaciones de polvo seco para inhalación
LT3191081T (lt) 2014-09-09 2020-07-10 Vectura Limited Vaisto forma, apimanti glikopiroliatą, būdas ir aparatūra
BR112017006842A2 (pt) 2014-10-07 2017-12-12 Lam Therapeutics Inc formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
US20160119692A1 (en) * 2014-10-24 2016-04-28 Sunshine Partners LLC Interactive system and method for viewer selection of objects in context while viewing television
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
WO2017218341A1 (en) 2016-06-17 2017-12-21 Axon Enterprise, Inc. Systems and methods for aligning event data
SG11201809630RA (en) * 2016-06-30 2018-11-29 Philip Morris Products Sa Nicotine particles
JP2019524648A (ja) * 2016-06-30 2019-09-05 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子および組成物
AU2017341815B2 (en) * 2016-10-14 2023-06-15 Pulmatrix Operating Company, Inc. Antifungal dry powders
KR20190126772A (ko) * 2017-03-07 2019-11-12 필립모리스 프로덕츠 에스.에이. 흡입 가능한 니코틴 제형, 및 이의 제조 및 사용 방법
WO2018223109A1 (en) 2017-06-02 2018-12-06 Csp Technologies, Inc. Inhaler and methods of using and making same
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JP7493449B2 (ja) 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CA3087698A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
WO2023128913A1 (en) * 2021-12-31 2023-07-06 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法
GB2633305A (en) 2023-08-30 2025-03-12 Envirohale Malta Holdings Ltd Nasal and pulmonary drug delivery
CN119055610A (zh) * 2024-08-27 2024-12-03 江苏谦仁生物科技有限公司 一种阿昔莫司胶囊及其制备方法
CN119371006B (zh) * 2024-11-06 2025-07-04 北京城市排水集团有限责任公司 一种长效缓释型污泥脱氮菌群调节药剂及制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
EP0470154B1 (en) 1989-04-28 1996-06-05 Riker Laboratories, Inc. Dry powder inhalation device
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
FR2747311B1 (fr) 1996-04-10 1998-08-14 Pf Medicament Inhalateur a poudre et a air comprime
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
EP0931595A1 (en) 1998-01-26 1999-07-28 Imra Europe S.A. A device for spraying a liquid
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE59904488D1 (de) 1998-11-13 2003-04-10 Jago Res Ag Muttenz Trockenpulver zur inhalation
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
ES2286881T3 (es) 1999-03-05 2007-12-01 Chiesi Farmaceutici S.P.A. Composiciones farmaceuticas en polvo mejoradas para inhalacion.
MXPA01012106A (es) 1999-05-27 2003-06-30 Acusphere Inc Matrices porosas de farmaco y metodo de fabricacion de las mismas.
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001072586A (ja) 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
RU2233273C3 (ru) 1999-09-16 2019-07-17 Мицубиси Танабе Φαρμα Корпорейшн Ароматические азотсодержащие 6-членные циклические соединения и фармацевтическая композиция
FI20002217A7 (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP1284735A4 (en) 2000-04-07 2006-01-11 Tap Pharmaceutical Prod Inc APOMORPHINE DERIVATIVES AND METHODS OF USE
AU782841B2 (en) 2000-04-17 2005-09-01 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) * 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
ES2292598T3 (es) 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
AU2001277230A1 (en) 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP1341536A4 (en) 2000-11-15 2007-08-01 Tap Pharmaceutical Prod Inc TREATMENT OF SEXUAL DYSFUNCTION CAUSED BY ANTIDEPRESSIVE MEDICATION BY APOMORPHINE
US20020086876A1 (en) 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
WO2002043700A2 (en) * 2000-11-30 2002-06-06 Vectura Limited Particles for use in a pharmaceutical composition
CA2429665C (en) * 2000-11-30 2013-10-22 Vectura Limited Method of making particles for use in a pharmaceutical composition
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
WO2002043693A2 (en) * 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
EP1353647B1 (en) 2000-12-27 2011-03-23 Gilead Sciences, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
GB0109384D0 (en) * 2001-04-12 2001-05-30 Vectura Ltd Pharmaceutical products, preparation and uses thereof
EP1392383A2 (en) 2001-05-10 2004-03-03 Vectura Delivery Devices Limited Inhalers
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
US20030175355A1 (en) * 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
US20040003341A1 (en) 2002-06-20 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for processing electronic forms for use with resource constrained devices
AU2003269284A1 (en) * 2002-10-11 2004-05-04 Pharmakodex Limited Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20060178394A1 (en) 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024009079A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation

Also Published As

Publication number Publication date
US20080127972A1 (en) 2008-06-05
EP2174653A1 (en) 2010-04-14
CN101106975A (zh) 2008-01-16
DE602005019192D1 (de) 2010-03-18
CN104146960A (zh) 2014-11-19
CA2589514A1 (en) 2006-06-01
EP1814521A1 (en) 2007-08-08
PT1814521E (pt) 2010-04-16
JP2008520307A (ja) 2008-06-19
PL1814521T3 (pl) 2010-07-30
PL2174653T3 (pl) 2014-11-28
ES2340599T3 (es) 2010-06-07
JP5339401B2 (ja) 2013-11-13
EP2311434A1 (en) 2011-04-20
PL2311434T3 (pl) 2015-12-31
US20110236492A1 (en) 2011-09-29
US9585834B2 (en) 2017-03-07
EP2174653B1 (en) 2014-05-14
ATE456363T1 (de) 2010-02-15
US20170216203A1 (en) 2017-08-03
SI2311434T1 (sl) 2015-11-30
HUE027465T2 (en) 2016-09-28
EP2949317B1 (en) 2017-01-04
GB0425758D0 (en) 2004-12-22
WO2006056812A1 (en) 2006-06-01
SI2174653T1 (sl) 2014-10-30
US9642800B2 (en) 2017-05-09
PT2311434E (pt) 2015-10-23
JP5579669B2 (ja) 2014-08-27
IN2014CN04336A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-04
JP2011201925A (ja) 2011-10-13
PT2174653E (pt) 2014-08-25
ES2490240T3 (es) 2014-09-03
US20160000709A1 (en) 2016-01-07
EP2311434B1 (en) 2015-07-08
DK2174653T3 (da) 2014-08-11
EP2949317A1 (en) 2015-12-02
CA2589514C (en) 2014-07-22
DK2311434T3 (en) 2015-10-05
EP1814521B1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
ES2548884T3 (es) Formulaciones de polvo seco para inhalador que comprenden partículas modificadas en la superficie con aditivos antiadherentes
ES2689704T3 (es) Partículas para usar en una composición farmacéutica
EP1617820B1 (en) Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
ES2699986T3 (es) Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
JP5705112B2 (ja) ドライパウダー吸入エアロゾル用の大径キャリア粒子を含む製剤
PT1663155E (pt) Composição em pó seco que compreende partículas co-moídas a jacto para inalação pulmonar
WO1999027911A1 (fr) Medicament en pastilles souples et procede de fabrication
US20240099967A1 (en) Inhalable composition of clofazimine and methods of use thereof
US20160128972A1 (en) Method for preventing influenza virus infection by administering a dry powder pharmaceutical composition
US20120321717A1 (en) Devices and pharmaceutical compositions for enhancing dosing efficiency
KR20190027844A (ko) 흡입용 의약 조성물
Malamatari Engineering nanoparticle agglomerates as dry powders for pulmonary drug delivery
ES2671546T3 (es) Composición en polvo seco que comprende partículas comolidas a chorro para inhalación pulmonar
Dhillon Engineering of combination particles for improved therapeutic efficacy
Crisp Solvent-mediated polymorphism and characterisation of inhaled pharmaceuticals
HK1239571A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
HK1080006B (en) Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
HK1080006A (en) Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
HK1160004B (en) Dry powder pharmaceutical composition for inhalation